Related Experiment Video
Updated: Nov 3, 2025

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
Published on: October 26, 2018
From Lab Formulation Development to CTM Manufacturing of KO-947 Injectable Drug Products: a Case Study and Lessons
Xiaohu Deng1,2, Pingda Ren3, Wanping Mai3
1Kura Oncology Inc., 12730 High Bluff Drive, Suite 400, San Diego, California, 92130, USA. xdeng1000@yahoo.com.
Abstract:
Formulation development of KO-947-K mesylate injectable drug products was described. Solution formulations were initially attempted, and key parameters such as drug concentration, buffer, pH, complexing agent, and tonicity modifying agent were carefully evaluated in the lab setting, mainly focusing on solubility and chemical stability. A lead solution formulation was advanced to a scaleup campaign. An unexpected stability issue was encountered, and the root cause was attributed to the heterogeneous liquid freezing process of the formulated solution at -20°C, which had not been captured in the lab setting. A lyophilized product was then designed to overcome the issue and supplied to the phase I clinical trial.
More Related Videos
Related Concept Videos
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

